JP2020512348A - 放射標識生体分子およびその使用 - Google Patents
放射標識生体分子およびその使用 Download PDFInfo
- Publication number
- JP2020512348A JP2020512348A JP2019553023A JP2019553023A JP2020512348A JP 2020512348 A JP2020512348 A JP 2020512348A JP 2019553023 A JP2019553023 A JP 2019553023A JP 2019553023 A JP2019553023 A JP 2019553023A JP 2020512348 A JP2020512348 A JP 2020512348A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- vhh
- biomolecule
- group
- radiolabeled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023062556A JP2023076712A (ja) | 2017-03-30 | 2023-04-07 | 放射標識生体分子およびその使用 |
| JP2025027120A JP2025071280A (ja) | 2017-03-30 | 2025-02-21 | 放射標識生体分子およびその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478754P | 2017-03-30 | 2017-03-30 | |
| US62/478,754 | 2017-03-30 | ||
| US201762500692P | 2017-05-03 | 2017-05-03 | |
| US62/500,692 | 2017-05-03 | ||
| US201762529532P | 2017-07-07 | 2017-07-07 | |
| US62/529,532 | 2017-07-07 | ||
| US201762583134P | 2017-11-08 | 2017-11-08 | |
| US62/583,134 | 2017-11-08 | ||
| PCT/IB2018/052211 WO2018178936A1 (en) | 2017-03-30 | 2018-03-29 | Radiolabeled biomolecules and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023062556A Division JP2023076712A (ja) | 2017-03-30 | 2023-04-07 | 放射標識生体分子およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512348A true JP2020512348A (ja) | 2020-04-23 |
| JP2020512348A5 JP2020512348A5 (cg-RX-API-DMAC7.html) | 2021-05-06 |
Family
ID=62017598
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553023A Withdrawn JP2020512348A (ja) | 2017-03-30 | 2018-03-29 | 放射標識生体分子およびその使用 |
| JP2023062556A Withdrawn JP2023076712A (ja) | 2017-03-30 | 2023-04-07 | 放射標識生体分子およびその使用 |
| JP2025027120A Pending JP2025071280A (ja) | 2017-03-30 | 2025-02-21 | 放射標識生体分子およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023062556A Withdrawn JP2023076712A (ja) | 2017-03-30 | 2023-04-07 | 放射標識生体分子およびその使用 |
| JP2025027120A Pending JP2025071280A (ja) | 2017-03-30 | 2025-02-21 | 放射標識生体分子およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200188541A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3600453A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2020512348A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110709106A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018178936A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024518097A (ja) * | 2021-05-14 | 2024-04-24 | パーデュー・リサーチ・ファウンデーション | 刷子縁膜酵素切断可能リンカーを持つ葉酸受容体標的コンジュゲート並びにガンのイメージング及び治療における使用方法 |
| JP2024534909A (ja) * | 2021-09-01 | 2024-09-26 | デューク ユニバーシティ | 放射性ハロゲンによるタンパク質の部位特異的標識のための試薬並びにその製造方法及び使用方法 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102899941B1 (ko) | 2019-05-24 | 2025-12-16 | 듀크 유니버시티 | 18f-방사선 표지된 생체 분자 |
| EP4058423A1 (en) | 2019-11-13 | 2022-09-21 | Duke University | Radiohalogen prosthetic moieties and radiolabeled biomolecules |
| EP3967674A1 (en) * | 2020-09-11 | 2022-03-16 | Precirix N.V. | Reactions of radioactive compounds facilitated by a solid phase |
| AU2023276697A1 (en) | 2022-05-23 | 2024-12-12 | Cereius, Inc. | Her2-binding agents and uses thereof |
| CN118388451A (zh) * | 2024-06-28 | 2024-07-26 | 四川大学 | 一种放射性标记的成纤维细胞活化蛋白抑制剂及其制备方法和应用 |
| WO2026128025A2 (en) | 2024-07-03 | 2026-06-18 | Solve Therapeutics, Inc. | Anti-ror2 antibody-radionuclide conjugates |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009521469A (ja) * | 2005-12-22 | 2009-06-04 | デューク ユニバーシティー | 薬剤をα−粒子エミッターによって放射標識するための安定化組成物および方法 |
| WO2014179715A1 (en) * | 2013-05-02 | 2014-11-06 | Duke University | Prosthetic compounds for labeling internalizing biomolecules |
| WO2016016021A1 (en) * | 2014-07-29 | 2016-02-04 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5302700A (en) | 1988-05-23 | 1994-04-12 | Duke University | Radiohalogenation conjugate technology |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| EP2247615B1 (en) | 2008-02-14 | 2014-07-30 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
| KR101389166B1 (ko) | 2011-01-12 | 2014-04-24 | 미쯔비시 레이온 가부시끼가이샤 | 활성 에너지선 경화성 수지 조성물, 미세 요철 구조체 및 미세 요철 구조체의 제조 방법 |
| KR101279584B1 (ko) | 2011-06-24 | 2013-06-28 | 대한민국 (식품의약품안전처장) | Erbb2 수용체에 선택적으로 결합하는 압타머 및 이의 용도 |
-
2018
- 2018-03-29 JP JP2019553023A patent/JP2020512348A/ja not_active Withdrawn
- 2018-03-29 EP EP18718637.4A patent/EP3600453A1/en active Pending
- 2018-03-29 CN CN201880036082.1A patent/CN110709106A/zh active Pending
- 2018-03-29 US US16/498,264 patent/US20200188541A1/en not_active Abandoned
- 2018-03-29 WO PCT/IB2018/052211 patent/WO2018178936A1/en not_active Ceased
-
2023
- 2023-04-07 JP JP2023062556A patent/JP2023076712A/ja not_active Withdrawn
-
2024
- 2024-11-13 US US18/946,772 patent/US20250073359A1/en active Pending
-
2025
- 2025-02-21 JP JP2025027120A patent/JP2025071280A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009521469A (ja) * | 2005-12-22 | 2009-06-04 | デューク ユニバーシティー | 薬剤をα−粒子エミッターによって放射標識するための安定化組成物および方法 |
| WO2014179715A1 (en) * | 2013-05-02 | 2014-11-06 | Duke University | Prosthetic compounds for labeling internalizing biomolecules |
| WO2016016021A1 (en) * | 2014-07-29 | 2016-02-04 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer |
Non-Patent Citations (4)
| Title |
|---|
| CATARINA XAVIER ET AL.: "Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPE", THE JOURNAL OF NUCLEAR MEDICINE, vol. 54, no. 5, JPN7022000802, 2013, pages 776 - 784, ISSN: 0005085071 * |
| GANESAN VAIDYANATHAN AND MICHAEL R ZALUTSKY: "Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for label", NATURE PROTOCOLS, vol. 2, no. 2, JPN7022000801, 2007, pages 282 - 286, ISSN: 0004712942 * |
| JAEYEON CHOI ET AL.: "N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric", NUCLEAR MEDICINE AND BIOLOGY, vol. 41, JPN6022007315, 2014, pages 802 - 812, ISSN: 0005085070 * |
| MAREK PRUSZYNSKI ET AL.: "Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoa", THE JOURNAL OF NUCLEAR MEDICINE, vol. 55, no. 4, JPN7022000800, 2014, pages 650 - 656, ISSN: 0004712941 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024518097A (ja) * | 2021-05-14 | 2024-04-24 | パーデュー・リサーチ・ファウンデーション | 刷子縁膜酵素切断可能リンカーを持つ葉酸受容体標的コンジュゲート並びにガンのイメージング及び治療における使用方法 |
| JP2024534909A (ja) * | 2021-09-01 | 2024-09-26 | デューク ユニバーシティ | 放射性ハロゲンによるタンパク質の部位特異的標識のための試薬並びにその製造方法及び使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200188541A1 (en) | 2020-06-18 |
| WO2018178936A1 (en) | 2018-10-04 |
| US20250073359A1 (en) | 2025-03-06 |
| EP3600453A1 (en) | 2020-02-05 |
| JP2023076712A (ja) | 2023-06-01 |
| CN110709106A (zh) | 2020-01-17 |
| JP2025071280A (ja) | 2025-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250073359A1 (en) | Radiolabeled biomolecules and their use | |
| JP7414370B2 (ja) | 配位子、スペーサー、ペプチドリンカーおよび生物分子からなる複合体 | |
| JP2022513256A (ja) | デュアルモード18f標識セラノスティック化合物及びその使用 | |
| KR20130132935A (ko) | Nota에 의해 복합체를 형성한 알루미늄―〔18〕플루오라이드로 표지된 her2 결합 펩티드 | |
| US20160074541A1 (en) | Prosthetic Compounds for Labeling Internalizing Biomolecules | |
| US20230340111A1 (en) | Antibody fragment against folr1 | |
| KR20170032463A (ko) | 암의 예방 및/또는 치료에서 사용하기 위한 방사성 표지 항체 단편 | |
| CA3222172A1 (en) | Methods and materials for combining biologics with multiple chelators | |
| US20240307564A1 (en) | Anti-cldn18.2 antibody conjugates | |
| KR20130132939A (ko) | 18f - 함유 유기실리콘 화합물로 표지된 her2 결합 펩티드 | |
| US20200197547A1 (en) | Anti-mesothelin radiolabelled single domain antibodies suitable for the imaging and treatment of cancers | |
| Nakashima et al. | Development of novel trifunctional chelating agents that enhance tumor retention of radioimmunoconjugates | |
| CN120813388A (zh) | 放射性金属标记抗体、放射性药物及化合物 | |
| KR20240099208A (ko) | EGFRvIII-표적화 화합물 및 그의 용도 | |
| US20240350682A1 (en) | Steap2-targeted compounds and use thereof | |
| WO2026083399A1 (en) | Conjugates and use of same for theranostics | |
| TW202400240A (zh) | 抗vegf抗體的放射性複合體及放射性醫藥 | |
| CN121041473A (zh) | 一种双功能性融合蛋白、放射性核素标记物及其应用 | |
| TW202607033A (zh) | 抗ror2抗體-放射性核種結合物 | |
| CA3285616A1 (en) | Method for producing radiolabeled antibody, radiolabeled antibody, and radiopharmaceutical | |
| WO2025195495A1 (zh) | 一种放射性核素偶联物及其制备方法和用途 | |
| WO2022211051A1 (ja) | 抗egfr抗体の放射性複合体、及び、放射性医薬 | |
| HK40106087A (en) | Anti-cldn18.2 antibody conjugates | |
| CN116077686A (zh) | 可酶切Linker及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210329 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210329 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220224 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220523 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220722 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220824 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230407 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230407 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20230418 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230425 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230426 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230623 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20250226 |